Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine plus midazolam versus midazolam alone for refractory status epilepticus
IRCT20221022056269N1Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ketamine and midazolam in status epilepticus (SE) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Shortening the duration of a long sustained seizure, Reducing the recurrence of seizures and 2 more. Started Nov 2022; status: completed.
02
Drugs
ketaminemidazolam
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on IRCT20221022056269N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221022056269N1.